Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.35 Analyst target: $11.64 Upside: 247.46%
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.